Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), Guangzhou Baiyunshan Pharmaceutical Holdings Co's 12-1 Month Momentum % is -17.26%.
FRA:GU5's 12-1 Month Momentum % is ranked worse than 63.49% of 126
companies
in the Medical Distribution industry
Industry Median: -9.865
vs FRA:GU5: -17.26
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Guangzhou Baiyunshan Pharmaceutical Holdings Co 12-1 Month Momentum % Related Terms
FRA:GU5 vs MCK, COR, CAH: 12-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co 12-1 Month Momentum % vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -17.26% mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a 12-1 Month Momentum % of -17.26% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #80 out of 126 companies in the Medical Distribution industry, placing it in the top 63.5%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's 12-1 Month Momentum % too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current 12-1 Month Momentum % is -17.26%. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #80 out of 126 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's 12-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #80 out of 126 companies for 12-1 Month Momentum %. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Distribution company?
A good 12-1 Month Momentum % depends on the Medical Distribution industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current 12-1 Month Momentum % is -17.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a current 12-1 Month Momentum % of -17.26%. The stock's GF Value™ is €2.04, compared to a current price of €1.44 — trading 29.4% below its estimated fair value. The current 12-1 Month Momentum % is -17.26%. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current 12-1 Month Momentum % is -17.26% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.44 is trading 29.4% below its estimated GF Value™ of €2.04.
Key valuation signals for FRA:GU5:
12-1 Month Momentum %: -17.26%
GF Value™: €2.04 vs. price of €1.44 (29.4% below fair value)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is a Chinese pharmaceutical and healthcare group listed in Hong Kong and Shanghai. It operates across the full industry chain, from research and manufacturing to distribution. Its Modern Chinese Medicine segment produces proprietary Chinese and natural medicines, while the Chemical Pharmaceutical segment covers chemical drugs, active pharmaceutical ingredients and intermediates. The group is known for consumer health brands such as Wanglaoji herbal tea, which sits within its natural beverages business, and it also sells consumer healthcare products. Its Pharmaceutical Commerce segment handles wholesale, retail and import/export of medicines and medical devices, supported by a large distribution network. Additional activities include biotechnology and medical services. Revenue comes from pharmaceutical manufacturing, consumer health and beverage sales, and distribution services, with the bulk of sales generated in mainland China and a smaller presence in international markets.
65GF Score
Get the complete analysis for FRA:GU5
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
